SCHEMBL4923715

SCHEMBL4923715

CC(=O)c1ccc(Oc2c[nH]c3ccccc23)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.60
MAPT P10636 4/20 0.53
RAB9A P51151 3/20 0.53
HPGD P15428 1/20 0.53
PBRM1 Q86U86 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
TP53 P04637 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
NR4A2 P43354 2/20 0.45
CREBBP Q92793 1/20 0.45
NPC1 O15118 3/20 0.44
IGF1R P08069 1/20 0.44
MET P08581 1/20 0.44
POLB P06746 1/20 0.44
GPR84 Q9NQS5 1/20 0.44
LMNA P02545 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KCNT1 Q5JUK3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979309 0.85 SLC22A6 (0.53) SLC22A6MAPTPBRM1SMN1; SMN2TP53
SCHEMBL31744932 0.81 SLC22A6 (0.50) SLC22A6PBRM1SMN1; SMN2TP53NPSR1
SCHEMBL31744658 0.81 SLC22A6 (0.50) SLC22A6MAPTRAB9AHPGDPBRM1
SCHEMBL31744738 0.81 SMN1; SMN2 (0.54) SLC22A6MAPTRAB9ASMN1; SMN2TP53
SCHEMBL13429126 0.80 KDM4E (0.50) MAPTRAB9AHPGDSMN1; SMN2NPC1
SCHEMBL28007152 0.80 SLC22A6 (0.51) SLC22A6MAPTPBRM1NPSR1NR4A2
SCHEMBL31744565 0.78 SLC22A6 (0.46) SLC22A6MAPTRAB9APBRM1SMN1; SMN2
SCHEMBL27396972 0.78 RHEB (0.51) SLC22A6MAPTTP53NPSR1LMNA
SCHEMBL4786081 0.77 MAPT (0.64) MAPTRAB9AHPGDSMN1; SMN2NPSR1
SCHEMBL4920498 0.77 STING1 (0.49) SLC22A6MAPTRAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139484-A1 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-06-12 US disclosed
EP-1803729-A1 1-( -D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139484-A1 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof SLC5A1, SLC5A2, UGGT1 SLC22A6 397/4885MAPT 1185/4885RAB9A 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.